尿路上皮癌FGFR3检测最佳实践专家解读:从患者识别到结果报告
本文由欧洲多学科专家组基于现有证据与临床经验,以叙述性综述形式提出局部晚期或转移性尿路上皮癌(LA/mUC)FGFR3检测的实践建议。推荐LA/mUC患者确诊时即行FGFR3检测,采用经验证的定量PCR或二代测序(NGS)方法,报告应按ESMO靶点临床可操作性量表分层标注,以支持厄达替尼等靶向治疗的及时可及。
要点
- LA/mUC患者应在确诊时即行FGFR3检测,以保障靶向治疗及时可及。
- 检测应采用经验证的定量PCR或NGS方法,报告中需按ESMO量表标注可操作性分层。
- ctDNA液体活检可作为组织检测的补充,但其在mUC中检测FGFR3的价值尚待进一步研究。
核心结论
- 在LA/mUC患者确诊时早期行FGFR3检测具有重要临床意义,可确保及时获得靶向治疗。
- 多学科协作是将分子检测整合进患者诊疗、支持有效个体化管理的关键。
研究设计与样本
- 本文为叙述性综述,由欧洲病理学家、分子生物学家、肿瘤学家和泌尿外科医生组成的多学科专家组制定实践建议。
- 建议基于对现有证据的批判性评价与集体临床经验形成。
主要发现
- 转移性尿路上皮癌存在多种基因组改变,其中FGFR3突变较常见,可影响生存结局与治疗反应。
- 厄达替尼在携带FGFR3改变的局部晚期或转移性尿路上皮癌患者中显示出生存改善。
关键数值与推荐
- LA/mUC患者应在确诊时接受FGFR3检测,现行指南支持这一做法。
- FGFR3检测应采用经验证的定量PCR或二代测序(NGS)方法。
- 分子实验室报告应包含按ESMO分子靶点临床可操作性量表分层列出的全部检出基因改变。
- 其他需考虑的因素包括年龄、衰弱状态、治疗适合性与生活质量。
临床怎么用
- 在LA/mUC确诊时即安排FGFR3检测,并选择经验证的定量PCR或NGS方法。
- 报告需按ESMO量表标注可操作性分层,便于筛选适合靶向治疗的患者。
- 通过多学科协作将分子检测整合进诊疗流程,实现个体化疾病管理。
局限性
- 经PCR和NGS对循环肿瘤DNA(ctDNA)进行液体活检可能作为组织检测的补充,但其检测mUC中FGFR3改变的价值尚需进一步研究确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Metastatic urothelial cancer (mUC) is associated with diverse genomic alterations, including frequent FGFR3 mutations that influence survival outcomes and treatment responses. Erdafitinib, a targeted therapy, has shown improved survival in patients with locally advanced (LA) or mUC harbouring FGFR3 alterations, reinforcing the importance of timely FGFR3 testing. OBJECTIVE: This article aims to provide practical guidance for step-by-step best practices in FGFR3 testing in mUC from sample acquisition to result reporting. EVIDENCE ACQUISITION: This narrative review presents practical recommendations for FGFR3 testing in mUC, developed by a multidisciplinary European panel of pathologists, molecular biologists, oncologists, and urologists, based on critical appraisal of current evidence and collective clinical experience. EVIDENCE SYNTHESIS: Patients with LA/mUC should undergo FGFR3 testing at diagnosis, as supported by the current guidelines. Other factors to consider include age, frailty, fitness for treatment, and quality of life. FGFR3 testing should be performed using validated quantitative polymerase chain reaction (PCR) assays or next-generation sequencing (NGS) methods. While liquid biopsy analysis on circulating tumour deoxyribonucleic acid (ctDNA) via PCR and NGS may offer a complementary approach to tissue testing, further research is needed to determine its value in detecting FGFR3 alterations in mUC. The molecular laboratory report should contain details of all detected genetic alterations by the European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets tier to indicate potential actionability. CONCLUSIONS: Early FGFR3 testing at diagnosis in patients with LA/mUC is clinically essential to ensure timely access to targeted therapies. Multidisciplinary collaboration is key to integrating molecular testing into patient care, supporting effective and personalised disease management.
引用
- Compérat EM, Hartmann A, Allory Y, et al. FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting. Eur Urol Oncol. 2026. PMID: 42448514. doi:10.1016/j.euo.2026.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。